Benitec Biopharma Inc. (BNTC)
Automate Your Wheel Strategy on BNTC
With Tiblio's Option Bot, you can configure your own wheel strategy including BNTC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BNTC
- Rev/Share 0.0
- Book/Share 2.5278
- PB 6.1754
- Debt/Equity 0.0098
- CurrentRatio 14.8036
- ROIC -0.3069
- MktCap 399619122.0
- FreeCF/Share -0.4841
- PFCF -21.386
- PE -22.7458
- Debt/Assets 0.0091
- DivYield 0
- ROE -0.3719
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BNTC | H.C. Wainwright | -- | Buy | -- | $28 | Dec. 16, 2024 |
| Initiation | BNTC | Robert W. Baird | -- | Outperform | -- | $30 | Dec. 13, 2024 |
| Initiation | BNTC | Oppenheimer | -- | Outperform | -- | $35 | Oct. 16, 2024 |
| Initiation | BNTC | Guggenheim | -- | Buy | -- | $17 | Sept. 12, 2024 |
News
Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Benitec Biopharma Limited (BNTC) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
Read More
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Read More
Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 83.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.
Read More
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Read More
Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year?
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.
Read More
Wall Street Analysts Believe Benitec Biopharma (BNTC) Could Rally 84.96%: Here's is How to Trade
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at an 85% upside potential for Benitec Biopharma (BNTC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
What Makes Benitec Biopharma (BNTC) a New Buy Stock
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Benitec Biopharma (BNTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct offering of 900,000 shares of its common stock with long-term investor Suvretta Capital.
Read More
Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Benitec Biopharma (BNTC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Read More
About Benitec Biopharma Inc. (BNTC)
- IPO Date 2014-06-24
- Website https://benitec.com
- Industry Biotechnology
- CEO Dr. Jerel A. Banks M.D., Ph.D.
- Employees 16